THE LATEST FROM RAKOVINA
Discovery in motion.
Rakovina Therapeutics Announces Presentation at the 13th Annual Tumour Models London Summit
DOWNLOAD December 3, 2024, Vancouver, British Columbia – Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, is...
Rakovina Therapeutics Announces 2024 Q3 Financial Results and Provides Corporate Update
DOWNLOAD All dollar amounts reflected in Canadian dollars unless otherwise stated November 29, 2024, Vancouver, British Columbia – Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
Rakovina Therapeutics Announces Increase in Private Placement Offering to $2.5 Million
DOwnload For Immediate Release Vancouver, British Columbia, November 28, 2024-- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response...
Rakovina Therapeutics Announces Private Placement Offering
DOWNLOAD The Company has received initial commitments totaling over $800,000 from strategic investors in connection with the Offering. For Immediate Release Vancouver, British Columbia, November 27, 2024 – Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or...
Rakovina Therapeutics Presents AI-Driven Drug Discovery Research at Society for Neuro-Oncology Annual Meeting
DOWNLOAD November 25, 2024, Vancouver, British Columbia – Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies,...
Rakovina Therapeutics Announces Upcoming Poster Presentation at the 29th Annual Society for Neuro-Oncology Meeting in Houston, Texas
Download November 20, 2024, Vancouver, British Columbia – Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, is...
Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain
download October 25, 2024, Vancouver, British Columbia – Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response targeting technologies, is...
Rakovina Therapeutics Announces Initial Drug Candidates from Deep Docking AI Molecule Discovery Platform
Company to present initial results of this research at the Society for Neuro-Oncology Annual Meeting in November Download October 23, 2024, Vancouver, British Columbia – Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company committed to advancing...
Rakovina Therapeutics and Variational AI Announce Drug Discovery Collaboration
DOWNLOAD Companies will jointly research DNA-damage response kinase targets to identify potential drug candidates for the treatment of cancer September 17, 2024, Vancouver, British...
Rakovina Therapeutics Announces 2024 Q2 Financial Results and Provides Corporate Update
DOWNLOAD All dollar amounts reflected in Canadian dollars unless otherwise stated. August 30, 2024, Vancouver, British Columbia -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed...
Rakovina Therapeutics Closes Previously Announced Over-subscribed Private Placement
DOWNLOAD All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 26, 2024 – Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed...
Rakovina Therapeutics Provides Update on Previously Announced Private Placement
DOWNLOAD All dollar amounts reflected in Canadian dollars unless otherwise stated. VANCOUVER, British Columbia, July 22, 2024 - Rakovina Therapeutics Inc. (TSX-V: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based on...
